nodes	percent_of_prediction	percent_of_DWPC	metapath
Tamoxifen—ABCC2—Spironolactone—dilated cardiomyopathy	0.219	0.349	CbGbCtD
Tamoxifen—ABCC2—Furosemide—dilated cardiomyopathy	0.15	0.239	CbGbCtD
Tamoxifen—CYP2C8—Spironolactone—dilated cardiomyopathy	0.106	0.168	CbGbCtD
Tamoxifen—ABCB1—Lisinopril—dilated cardiomyopathy	0.0811	0.129	CbGbCtD
Tamoxifen—ABCB1—Spironolactone—dilated cardiomyopathy	0.0714	0.114	CbGbCtD
Tamoxifen—Accidental ingestion—Furosemide—dilated cardiomyopathy	0.0233	0.0917	CcSEcCtD
Tamoxifen—Accidental exposure to product—Furosemide—dilated cardiomyopathy	0.0233	0.0917	CcSEcCtD
Tamoxifen—Pemphigoid—Furosemide—dilated cardiomyopathy	0.0175	0.069	CcSEcCtD
Tamoxifen—CYP2C9—cardial valve—dilated cardiomyopathy	0.0138	0.239	CbGeAlD
Tamoxifen—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.00729	0.0287	CcSEcCtD
Tamoxifen—Breast pain—Spironolactone—dilated cardiomyopathy	0.00463	0.0182	CcSEcCtD
Tamoxifen—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00459	0.0181	CcSEcCtD
Tamoxifen—EBPL—heart—dilated cardiomyopathy	0.00456	0.0789	CbGeAlD
Tamoxifen—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00414	0.0163	CcSEcCtD
Tamoxifen—ESRRA—cardiac ventricle—dilated cardiomyopathy	0.00386	0.0669	CbGeAlD
Tamoxifen—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00371	0.0146	CcSEcCtD
Tamoxifen—ESRRA—myocardium—dilated cardiomyopathy	0.00363	0.0629	CbGeAlD
Tamoxifen—SULT1A1—heart—dilated cardiomyopathy	0.00362	0.0627	CbGeAlD
Tamoxifen—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00335	0.0132	CcSEcCtD
Tamoxifen—Appetite absent—Lisinopril—dilated cardiomyopathy	0.00331	0.013	CcSEcCtD
Tamoxifen—Thrombosis—Furosemide—dilated cardiomyopathy	0.0031	0.0122	CcSEcCtD
Tamoxifen—Blister—Furosemide—dilated cardiomyopathy	0.00305	0.012	CcSEcCtD
Tamoxifen—Blindness—Lisinopril—dilated cardiomyopathy	0.00298	0.0117	CcSEcCtD
Tamoxifen—Cholestasis—Furosemide—dilated cardiomyopathy	0.00289	0.0114	CcSEcCtD
Tamoxifen—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00271	0.0107	CcSEcCtD
Tamoxifen—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00264	0.0104	CcSEcCtD
Tamoxifen—DHCR7—heart—dilated cardiomyopathy	0.00258	0.0446	CbGeAlD
Tamoxifen—ESRRA—heart—dilated cardiomyopathy	0.00254	0.0439	CbGeAlD
Tamoxifen—Drug interaction—Furosemide—dilated cardiomyopathy	0.00237	0.00932	CcSEcCtD
Tamoxifen—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00233	0.00918	CcSEcCtD
Tamoxifen—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00229	0.009	CcSEcCtD
Tamoxifen—Vasculitis—Furosemide—dilated cardiomyopathy	0.00225	0.00886	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00224	0.00881	CcSEcCtD
Tamoxifen—FMO3—heart—dilated cardiomyopathy	0.00223	0.0385	CbGeAlD
Tamoxifen—DHCR7—cardiac atrium—dilated cardiomyopathy	0.0022	0.0381	CbGeAlD
Tamoxifen—ESRRA—cardiac atrium—dilated cardiomyopathy	0.00217	0.0376	CbGeAlD
Tamoxifen—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00202	0.00794	CcSEcCtD
Tamoxifen—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00197	0.00774	CcSEcCtD
Tamoxifen—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00192	0.00755	CcSEcCtD
Tamoxifen—Breast pain—Lisinopril—dilated cardiomyopathy	0.00189	0.00744	CcSEcCtD
Tamoxifen—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00186	0.00733	CcSEcCtD
Tamoxifen—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00181	0.00713	CcSEcCtD
Tamoxifen—Swelling—Furosemide—dilated cardiomyopathy	0.00181	0.00712	CcSEcCtD
Tamoxifen—Cough increased—Lisinopril—dilated cardiomyopathy	0.0018	0.00709	CcSEcCtD
Tamoxifen—SIGMAR1—cardiac ventricle—dilated cardiomyopathy	0.0018	0.0311	CbGeAlD
Tamoxifen—Alopecia—Spironolactone—dilated cardiomyopathy	0.00179	0.00705	CcSEcCtD
Tamoxifen—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00178	0.00699	CcSEcCtD
Tamoxifen—CES1—heart—dilated cardiomyopathy	0.00176	0.0304	CbGeAlD
Tamoxifen—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00173	0.00682	CcSEcCtD
Tamoxifen—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0017	0.00668	CcSEcCtD
Tamoxifen—SIGMAR1—myocardium—dilated cardiomyopathy	0.00169	0.0293	CbGeAlD
Tamoxifen—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00169	0.00665	CcSEcCtD
Tamoxifen—Thirst—Furosemide—dilated cardiomyopathy	0.00168	0.0066	CcSEcCtD
Tamoxifen—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00167	0.00657	CcSEcCtD
Tamoxifen—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00167	0.00657	CcSEcCtD
Tamoxifen—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00165	0.00649	CcSEcCtD
Tamoxifen—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00158	0.00622	CcSEcCtD
Tamoxifen—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00156	0.00616	CcSEcCtD
Tamoxifen—ESR2—heart—dilated cardiomyopathy	0.00152	0.0264	CbGeAlD
Tamoxifen—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00149	0.00588	CcSEcCtD
Tamoxifen—Discomfort—Spironolactone—dilated cardiomyopathy	0.00148	0.00584	CcSEcCtD
Tamoxifen—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00147	0.0058	CcSEcCtD
Tamoxifen—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00144	0.00565	CcSEcCtD
Tamoxifen—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00141	0.00555	CcSEcCtD
Tamoxifen—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00137	0.00539	CcSEcCtD
Tamoxifen—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00135	0.00532	CcSEcCtD
Tamoxifen—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00133	0.00524	CcSEcCtD
Tamoxifen—Injury—Lisinopril—dilated cardiomyopathy	0.0013	0.00512	CcSEcCtD
Tamoxifen—Orphenadrine—SCN5A—dilated cardiomyopathy	0.00125	0.493	CrCbGaD
Tamoxifen—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00124	0.0049	CcSEcCtD
Tamoxifen—Arthritis—Lisinopril—dilated cardiomyopathy	0.00123	0.00485	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00122	0.0048	CcSEcCtD
Tamoxifen—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00121	0.0209	CbGeAlD
Tamoxifen—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.0012	0.00471	CcSEcCtD
Tamoxifen—SIGMAR1—heart—dilated cardiomyopathy	0.00118	0.0204	CbGeAlD
Tamoxifen—Sweating—Furosemide—dilated cardiomyopathy	0.00118	0.00464	CcSEcCtD
Tamoxifen—Urticaria—Spironolactone—dilated cardiomyopathy	0.00114	0.0045	CcSEcCtD
Tamoxifen—CYP1B1—heart—dilated cardiomyopathy	0.00112	0.0194	CbGeAlD
Tamoxifen—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00112	0.00441	CcSEcCtD
Tamoxifen—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00108	0.00424	CcSEcCtD
Tamoxifen—Visual impairment—Furosemide—dilated cardiomyopathy	0.00106	0.00418	CcSEcCtD
Tamoxifen—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00106	0.00418	CcSEcCtD
Tamoxifen—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00104	0.00411	CcSEcCtD
Tamoxifen—ESR1—heart—dilated cardiomyopathy	0.00104	0.018	CbGeAlD
Tamoxifen—Influenza—Lisinopril—dilated cardiomyopathy	0.00103	0.00407	CcSEcCtD
Tamoxifen—Pruritus—Spironolactone—dilated cardiomyopathy	0.00102	0.00401	CcSEcCtD
Tamoxifen—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00101	0.00399	CcSEcCtD
Tamoxifen—SIGMAR1—cardiac atrium—dilated cardiomyopathy	0.00101	0.0175	CbGeAlD
Tamoxifen—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00101	0.00397	CcSEcCtD
Tamoxifen—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000994	0.00391	CcSEcCtD
Tamoxifen—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000985	0.00388	CcSEcCtD
Tamoxifen—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000985	0.00388	CcSEcCtD
Tamoxifen—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000982	0.00387	CcSEcCtD
Tamoxifen—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000967	0.00381	CcSEcCtD
Tamoxifen—Erythema—Furosemide—dilated cardiomyopathy	0.00096	0.00378	CcSEcCtD
Tamoxifen—Dizziness—Spironolactone—dilated cardiomyopathy	0.000952	0.00375	CcSEcCtD
Tamoxifen—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000952	0.00375	CcSEcCtD
Tamoxifen—Weight increased—Lisinopril—dilated cardiomyopathy	0.000941	0.0037	CcSEcCtD
Tamoxifen—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00094	0.0037	CcSEcCtD
Tamoxifen—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000935	0.00368	CcSEcCtD
Tamoxifen—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000927	0.00365	CcSEcCtD
Tamoxifen—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000923	0.00363	CcSEcCtD
Tamoxifen—Depression—Lisinopril—dilated cardiomyopathy	0.000919	0.00362	CcSEcCtD
Tamoxifen—Vomiting—Spironolactone—dilated cardiomyopathy	0.000916	0.00361	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000914	0.0036	CcSEcCtD
Tamoxifen—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000909	0.00358	CcSEcCtD
Tamoxifen—Rash—Spironolactone—dilated cardiomyopathy	0.000908	0.00358	CcSEcCtD
Tamoxifen—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000907	0.00357	CcSEcCtD
Tamoxifen—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000904	0.00356	CcSEcCtD
Tamoxifen—Headache—Spironolactone—dilated cardiomyopathy	0.000902	0.00355	CcSEcCtD
Tamoxifen—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000896	0.00353	CcSEcCtD
Tamoxifen—Anaemia—Furosemide—dilated cardiomyopathy	0.000887	0.00349	CcSEcCtD
Tamoxifen—Sweating—Lisinopril—dilated cardiomyopathy	0.000884	0.00348	CcSEcCtD
Tamoxifen—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000865	0.00341	CcSEcCtD
Tamoxifen—Leukopenia—Furosemide—dilated cardiomyopathy	0.000859	0.00338	CcSEcCtD
Tamoxifen—Nausea—Spironolactone—dilated cardiomyopathy	0.000855	0.00337	CcSEcCtD
Tamoxifen—ABCG2—heart—dilated cardiomyopathy	0.000835	0.0145	CbGeAlD
Tamoxifen—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000828	0.00326	CcSEcCtD
Tamoxifen—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000821	0.00323	CcSEcCtD
Tamoxifen—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000815	0.00321	CcSEcCtD
Tamoxifen—Dry mouth—Furosemide—dilated cardiomyopathy	0.000799	0.00315	CcSEcCtD
Tamoxifen—CYP1A1—heart—dilated cardiomyopathy	0.000793	0.0137	CbGeAlD
Tamoxifen—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000782	0.00308	CcSEcCtD
Tamoxifen—CYP2B6—heart—dilated cardiomyopathy	0.00077	0.0133	CbGeAlD
Tamoxifen—Flushing—Lisinopril—dilated cardiomyopathy	0.000768	0.00302	CcSEcCtD
Tamoxifen—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000767	0.00302	CcSEcCtD
Tamoxifen—CYP2C9—heart—dilated cardiomyopathy	0.000763	0.0132	CbGeAlD
Tamoxifen—Diphenhydramine—SLC22A5—dilated cardiomyopathy	0.000759	0.3	CrCbGaD
Tamoxifen—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000758	0.00298	CcSEcCtD
Tamoxifen—Anorexia—Furosemide—dilated cardiomyopathy	0.000747	0.00294	CcSEcCtD
Tamoxifen—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000739	0.00291	CcSEcCtD
Tamoxifen—Alopecia—Lisinopril—dilated cardiomyopathy	0.000731	0.00288	CcSEcCtD
Tamoxifen—Erythema—Lisinopril—dilated cardiomyopathy	0.00072	0.00284	CcSEcCtD
Tamoxifen—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000705	0.00278	CcSEcCtD
Tamoxifen—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000704	0.00277	CcSEcCtD
Tamoxifen—Back pain—Lisinopril—dilated cardiomyopathy	0.000697	0.00274	CcSEcCtD
Tamoxifen—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000693	0.00273	CcSEcCtD
Tamoxifen—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000681	0.00268	CcSEcCtD
Tamoxifen—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.000678	0.0117	CbGeAlD
Tamoxifen—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000676	0.00266	CcSEcCtD
Tamoxifen—Fatigue—Furosemide—dilated cardiomyopathy	0.000676	0.00266	CcSEcCtD
Tamoxifen—Pain—Furosemide—dilated cardiomyopathy	0.00067	0.00264	CcSEcCtD
Tamoxifen—Constipation—Furosemide—dilated cardiomyopathy	0.00067	0.00264	CcSEcCtD
Tamoxifen—Anaemia—Lisinopril—dilated cardiomyopathy	0.000666	0.00262	CcSEcCtD
Tamoxifen—Angioedema—Lisinopril—dilated cardiomyopathy	0.000658	0.00259	CcSEcCtD
Tamoxifen—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000645	0.00254	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000641	0.00252	CcSEcCtD
Tamoxifen—Cough—Lisinopril—dilated cardiomyopathy	0.000629	0.00247	CcSEcCtD
Tamoxifen—Urticaria—Furosemide—dilated cardiomyopathy	0.000622	0.00245	CcSEcCtD
Tamoxifen—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000619	0.00244	CcSEcCtD
Tamoxifen—Chest pain—Lisinopril—dilated cardiomyopathy	0.000613	0.00241	CcSEcCtD
Tamoxifen—Myalgia—Lisinopril—dilated cardiomyopathy	0.000613	0.00241	CcSEcCtD
Tamoxifen—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000613	0.00241	CcSEcCtD
Tamoxifen—Anxiety—Lisinopril—dilated cardiomyopathy	0.000611	0.00241	CcSEcCtD
Tamoxifen—Discomfort—Lisinopril—dilated cardiomyopathy	0.000606	0.00239	CcSEcCtD
Tamoxifen—Dry mouth—Lisinopril—dilated cardiomyopathy	0.0006	0.00236	CcSEcCtD
Tamoxifen—Oedema—Lisinopril—dilated cardiomyopathy	0.000588	0.00231	CcSEcCtD
Tamoxifen—Infection—Lisinopril—dilated cardiomyopathy	0.000584	0.0023	CcSEcCtD
Tamoxifen—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000577	0.00227	CcSEcCtD
Tamoxifen—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000576	0.00227	CcSEcCtD
Tamoxifen—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000568	0.00224	CcSEcCtD
Tamoxifen—Asthenia—Furosemide—dilated cardiomyopathy	0.000562	0.00221	CcSEcCtD
Tamoxifen—Anorexia—Lisinopril—dilated cardiomyopathy	0.00056	0.00221	CcSEcCtD
Tamoxifen—Pruritus—Furosemide—dilated cardiomyopathy	0.000554	0.00218	CcSEcCtD
Tamoxifen—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000536	0.00211	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000536	0.00211	CcSEcCtD
Tamoxifen—Insomnia—Lisinopril—dilated cardiomyopathy	0.000532	0.00209	CcSEcCtD
Tamoxifen—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000528	0.00208	CcSEcCtD
Tamoxifen—Phenoxybenzamine—ADRB2—dilated cardiomyopathy	0.000526	0.208	CrCbGaD
Tamoxifen—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000524	0.00206	CcSEcCtD
Tamoxifen—Dizziness—Furosemide—dilated cardiomyopathy	0.000518	0.00204	CcSEcCtD
Tamoxifen—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000518	0.00204	CcSEcCtD
Tamoxifen—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000511	0.00201	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000508	0.002	CcSEcCtD
Tamoxifen—Fatigue—Lisinopril—dilated cardiomyopathy	0.000507	0.002	CcSEcCtD
Tamoxifen—Pain—Lisinopril—dilated cardiomyopathy	0.000503	0.00198	CcSEcCtD
Tamoxifen—Constipation—Lisinopril—dilated cardiomyopathy	0.000503	0.00198	CcSEcCtD
Tamoxifen—Vomiting—Furosemide—dilated cardiomyopathy	0.000498	0.00196	CcSEcCtD
Tamoxifen—Rash—Furosemide—dilated cardiomyopathy	0.000494	0.00195	CcSEcCtD
Tamoxifen—Dermatitis—Furosemide—dilated cardiomyopathy	0.000494	0.00194	CcSEcCtD
Tamoxifen—Headache—Furosemide—dilated cardiomyopathy	0.000491	0.00193	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000481	0.00189	CcSEcCtD
Tamoxifen—Urticaria—Lisinopril—dilated cardiomyopathy	0.000467	0.00184	CcSEcCtD
Tamoxifen—Nausea—Furosemide—dilated cardiomyopathy	0.000465	0.00183	CcSEcCtD
Tamoxifen—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000465	0.00183	CcSEcCtD
Tamoxifen—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000433	0.00171	CcSEcCtD
Tamoxifen—Asthenia—Lisinopril—dilated cardiomyopathy	0.000422	0.00166	CcSEcCtD
Tamoxifen—Pruritus—Lisinopril—dilated cardiomyopathy	0.000416	0.00164	CcSEcCtD
Tamoxifen—ABCB1—heart—dilated cardiomyopathy	0.000412	0.00713	CbGeAlD
Tamoxifen—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000402	0.00158	CcSEcCtD
Tamoxifen—Dizziness—Lisinopril—dilated cardiomyopathy	0.000389	0.00153	CcSEcCtD
Tamoxifen—Vomiting—Lisinopril—dilated cardiomyopathy	0.000374	0.00147	CcSEcCtD
Tamoxifen—Rash—Lisinopril—dilated cardiomyopathy	0.000371	0.00146	CcSEcCtD
Tamoxifen—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00037	0.00146	CcSEcCtD
Tamoxifen—Headache—Lisinopril—dilated cardiomyopathy	0.000368	0.00145	CcSEcCtD
Tamoxifen—Nausea—Lisinopril—dilated cardiomyopathy	0.000349	0.00137	CcSEcCtD
Tamoxifen—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000127	0.00216	CbGpPWpGaD
Tamoxifen—EBP—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000126	0.00214	CbGpPWpGaD
Tamoxifen—ESR2—Gene Expression—NR3C2—dilated cardiomyopathy	0.000125	0.00213	CbGpPWpGaD
Tamoxifen—ESRRA—Gene Expression—NPPA—dilated cardiomyopathy	0.000124	0.0021	CbGpPWpGaD
Tamoxifen—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000123	0.0021	CbGpPWpGaD
Tamoxifen—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000123	0.0021	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000121	0.00206	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—SDHA—dilated cardiomyopathy	0.000121	0.00206	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000118	0.00201	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000118	0.00201	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000118	0.002	CbGpPWpGaD
Tamoxifen—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000118	0.002	CbGpPWpGaD
Tamoxifen—CYP1B1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000118	0.002	CbGpPWpGaD
Tamoxifen—ESR1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000115	0.00195	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000115	0.00195	CbGpPWpGaD
Tamoxifen—ESR1—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.000113	0.00192	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000113	0.00192	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000112	0.0019	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000111	0.00189	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00011	0.00187	CbGpPWpGaD
Tamoxifen—ESR1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000109	0.00186	CbGpPWpGaD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000109	0.00185	CbGpPWpGaD
Tamoxifen—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000109	0.00185	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000106	0.00181	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000106	0.00179	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000105	0.00179	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—ANKRD1—dilated cardiomyopathy	0.000105	0.00178	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000103	0.00175	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000103	0.00175	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000101	0.00171	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	9.92e-05	0.00169	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—TAZ—dilated cardiomyopathy	9.87e-05	0.00168	CbGpPWpGaD
Tamoxifen—FMO3—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	9.86e-05	0.00168	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	9.86e-05	0.00168	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	9.76e-05	0.00166	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	9.67e-05	0.00164	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.55e-05	0.00162	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	9.17e-05	0.00156	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	9.09e-05	0.00155	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—SDHA—dilated cardiomyopathy	8.93e-05	0.00152	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	8.84e-05	0.0015	CbGpPWpGaD
Tamoxifen—CYP1A1—PPARA activates gene expression—CD36—dilated cardiomyopathy	8.84e-05	0.0015	CbGpPWpGaD
Tamoxifen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	8.65e-05	0.00147	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.63e-05	0.00147	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	8.55e-05	0.00145	CbGpPWpGaD
Tamoxifen—ESR1—Regulation of Telomerase—EGFR—dilated cardiomyopathy	8.4e-05	0.00143	CbGpPWpGaD
Tamoxifen—ESR1—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	8.25e-05	0.0014	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	8.25e-05	0.0014	CbGpPWpGaD
Tamoxifen—ESR2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	8.16e-05	0.00139	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	8.12e-05	0.00138	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	8.08e-05	0.00137	CbGpPWpGaD
Tamoxifen—CYP1A1—PPARA activates gene expression—AGT—dilated cardiomyopathy	7.96e-05	0.00135	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—ANKRD1—dilated cardiomyopathy	7.92e-05	0.00135	CbGpPWpGaD
Tamoxifen—ESR2—Gene Expression—NPPA—dilated cardiomyopathy	7.87e-05	0.00134	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	7.87e-05	0.00134	CbGpPWpGaD
Tamoxifen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	7.79e-05	0.00132	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—ANKRD1—dilated cardiomyopathy	7.63e-05	0.0013	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	7.61e-05	0.00129	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	7.61e-05	0.00129	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—TAZ—dilated cardiomyopathy	7.45e-05	0.00127	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	7.4e-05	0.00126	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.29e-05	0.00124	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	7.24e-05	0.00123	CbGpPWpGaD
Tamoxifen—CYP1A1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	7.24e-05	0.00123	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—TAZ—dilated cardiomyopathy	7.17e-05	0.00122	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	7.07e-05	0.0012	CbGpPWpGaD
Tamoxifen—ESR2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.94e-05	0.00118	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	6.94e-05	0.00118	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	6.88e-05	0.00117	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—SDHA—dilated cardiomyopathy	6.74e-05	0.00115	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism—GPX1—dilated cardiomyopathy	6.74e-05	0.00115	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	6.73e-05	0.00114	CbGpPWpGaD
Tamoxifen—SULT1A1—Metabolism—GPX1—dilated cardiomyopathy	6.61e-05	0.00112	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism—CD36—dilated cardiomyopathy	6.56e-05	0.00112	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	6.53e-05	0.00111	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—SDHA—dilated cardiomyopathy	6.49e-05	0.0011	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	6.47e-05	0.0011	CbGpPWpGaD
Tamoxifen—SULT1A1—Metabolism—CD36—dilated cardiomyopathy	6.44e-05	0.00109	CbGpPWpGaD
Tamoxifen—ESR1—Signaling by ERBB4—RAF1—dilated cardiomyopathy	6.43e-05	0.00109	CbGpPWpGaD
Tamoxifen—EBP—Metabolism—GPX1—dilated cardiomyopathy	6.39e-05	0.00109	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.32e-05	0.00108	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—NR3C2—dilated cardiomyopathy	6.32e-05	0.00107	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—ANKRD1—dilated cardiomyopathy	6.31e-05	0.00107	CbGpPWpGaD
Tamoxifen—EBP—Metabolism—CD36—dilated cardiomyopathy	6.22e-05	0.00106	CbGpPWpGaD
Tamoxifen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	5.96e-05	0.00101	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—TAZ—dilated cardiomyopathy	5.93e-05	0.00101	CbGpPWpGaD
Tamoxifen—DHCR7—Metabolism—AGT—dilated cardiomyopathy	5.91e-05	0.001	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	5.9e-05	0.001	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	5.85e-05	0.000994	CbGpPWpGaD
Tamoxifen—SULT1A1—Metabolism—AGT—dilated cardiomyopathy	5.8e-05	0.000986	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.71e-05	0.00097	CbGpPWpGaD
Tamoxifen—EBP—Metabolism—AGT—dilated cardiomyopathy	5.6e-05	0.000952	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5.55e-05	0.000944	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5.55e-05	0.000944	CbGpPWpGaD
Tamoxifen—FMO1—Metabolism—GPX1—dilated cardiomyopathy	5.49e-05	0.000933	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.45e-05	0.000926	CbGpPWpGaD
Tamoxifen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	5.36e-05	0.000912	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—SDHA—dilated cardiomyopathy	5.36e-05	0.000911	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	5.36e-05	0.000911	CbGpPWpGaD
Tamoxifen—FMO1—Metabolism—CD36—dilated cardiomyopathy	5.35e-05	0.000909	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.3e-05	0.000902	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.16e-05	0.000878	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—GPX1—dilated cardiomyopathy	5.1e-05	0.000868	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—ANKRD1—dilated cardiomyopathy	5.09e-05	0.000865	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	4.98e-05	0.000847	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	4.97e-05	0.000845	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—CD36—dilated cardiomyopathy	4.97e-05	0.000845	CbGpPWpGaD
Tamoxifen—CYP19A1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	4.96e-05	0.000842	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	4.85e-05	0.000824	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	4.85e-05	0.000824	CbGpPWpGaD
Tamoxifen—FMO1—Metabolism—AGT—dilated cardiomyopathy	4.81e-05	0.000819	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—TAZ—dilated cardiomyopathy	4.78e-05	0.000813	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.77e-05	0.000812	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	4.7e-05	0.000799	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	4.68e-05	0.000796	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	4.68e-05	0.000795	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	4.62e-05	0.000785	CbGpPWpGaD
Tamoxifen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	4.62e-05	0.000785	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	4.52e-05	0.000769	CbGpPWpGaD
Tamoxifen—ESRRA—Metabolism—AGT—dilated cardiomyopathy	4.48e-05	0.000761	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	4.44e-05	0.000754	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	4.42e-05	0.000751	CbGpPWpGaD
Tamoxifen—ESR1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	4.41e-05	0.00075	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	4.36e-05	0.000742	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—SDHA—dilated cardiomyopathy	4.33e-05	0.000735	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	4.31e-05	0.000732	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	4.28e-05	0.000727	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	4.24e-05	0.00072	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	4.23e-05	0.000719	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.11e-05	0.000698	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	4.05e-05	0.000688	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4e-05	0.00068	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	3.99e-05	0.000679	CbGpPWpGaD
Tamoxifen—ESR1—Gene Expression—NPPA—dilated cardiomyopathy	3.97e-05	0.000675	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.96e-05	0.000673	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—GPX1—dilated cardiomyopathy	3.93e-05	0.000667	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.85e-05	0.000655	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	3.84e-05	0.000654	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—CD36—dilated cardiomyopathy	3.82e-05	0.00065	CbGpPWpGaD
Tamoxifen—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	3.75e-05	0.000638	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	3.75e-05	0.000638	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	3.68e-05	0.000625	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	3.66e-05	0.000623	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	3.61e-05	0.000614	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.6e-05	0.000612	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	3.54e-05	0.000601	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	3.53e-05	0.0006	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	3.51e-05	0.000596	CbGpPWpGaD
Tamoxifen—ESR1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	3.5e-05	0.000595	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.47e-05	0.00059	CbGpPWpGaD
Tamoxifen—FMO3—Metabolism—AGT—dilated cardiomyopathy	3.44e-05	0.000585	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	3.32e-05	0.000565	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	3.3e-05	0.00056	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—GPX1—dilated cardiomyopathy	3.29e-05	0.000559	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	3.27e-05	0.000556	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—CD36—dilated cardiomyopathy	3.2e-05	0.000545	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	3.19e-05	0.000542	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	3.01e-05	0.000511	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	3e-05	0.000509	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	2.98e-05	0.000507	CbGpPWpGaD
Tamoxifen—UGT1A4—Metabolism—AGT—dilated cardiomyopathy	2.88e-05	0.00049	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	2.84e-05	0.000482	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	2.82e-05	0.000479	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	2.55e-05	0.000433	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.5e-05	0.000425	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.44e-05	0.000414	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—GPX1—dilated cardiomyopathy	2.43e-05	0.000412	CbGpPWpGaD
Tamoxifen—ABCC2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.39e-05	0.000407	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.37e-05	0.000403	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—CD36—dilated cardiomyopathy	2.36e-05	0.000402	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.31e-05	0.000393	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.23e-05	0.00038	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.22e-05	0.000377	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.22e-05	0.000377	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.18e-05	0.00037	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.17e-05	0.00037	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.14e-05	0.000363	CbGpPWpGaD
Tamoxifen—ABCB11—Metabolism—AGT—dilated cardiomyopathy	2.13e-05	0.000362	CbGpPWpGaD
Tamoxifen—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.08e-05	0.000354	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.06e-05	0.000351	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	2e-05	0.00034	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.99e-05	0.000339	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.97e-05	0.000334	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.96e-05	0.000333	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.94e-05	0.000331	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.94e-05	0.00033	CbGpPWpGaD
Tamoxifen—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.85e-05	0.000315	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—GPX1—dilated cardiomyopathy	1.83e-05	0.000311	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.82e-05	0.000309	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—CD36—dilated cardiomyopathy	1.78e-05	0.000303	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.77e-05	0.000301	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—GPX1—dilated cardiomyopathy	1.76e-05	0.0003	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.75e-05	0.000297	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—CD36—dilated cardiomyopathy	1.72e-05	0.000292	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.71e-05	0.00029	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.62e-05	0.000275	CbGpPWpGaD
Tamoxifen—CYP19A1—Metabolism—AGT—dilated cardiomyopathy	1.6e-05	0.000273	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	1.6e-05	0.000273	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.59e-05	0.000271	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	1.59e-05	0.00027	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—CD36—dilated cardiomyopathy	1.56e-05	0.000265	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.55e-05	0.000264	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	1.55e-05	0.000263	CbGpPWpGaD
Tamoxifen—CYP1B1—Metabolism—AGT—dilated cardiomyopathy	1.55e-05	0.000263	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.51e-05	0.000257	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—GPX1—dilated cardiomyopathy	1.46e-05	0.000248	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—CD36—dilated cardiomyopathy	1.42e-05	0.000241	CbGpPWpGaD
Tamoxifen—ABCG2—Metabolism—AGT—dilated cardiomyopathy	1.41e-05	0.000239	CbGpPWpGaD
Tamoxifen—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	1.39e-05	0.000237	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.39e-05	0.000237	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.36e-05	0.000232	CbGpPWpGaD
Tamoxifen—CYP2A6—Metabolism—AGT—dilated cardiomyopathy	1.28e-05	0.000217	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.26e-05	0.000214	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—AGT—dilated cardiomyopathy	1.2e-05	0.000204	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	1.18e-05	0.0002	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	1.15e-05	0.000196	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	1.15e-05	0.000195	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	1.14e-05	0.000195	CbGpPWpGaD
Tamoxifen—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.13e-05	0.000191	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	1.12e-05	0.000191	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	1.12e-05	0.00019	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	1.09e-05	0.000184	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	1.06e-05	0.00018	CbGpPWpGaD
Tamoxifen—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	1.03e-05	0.000175	CbGpPWpGaD
Tamoxifen—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	1.01e-05	0.000172	CbGpPWpGaD
Tamoxifen—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	1.01e-05	0.000171	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	9.95e-06	0.000169	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	9.69e-06	0.000165	CbGpPWpGaD
Tamoxifen—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	9.51e-06	0.000162	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	8.88e-06	0.000151	CbGpPWpGaD
Tamoxifen—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	8.72e-06	0.000148	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	8.67e-06	0.000147	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	8.65e-06	0.000147	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—CD36—dilated cardiomyopathy	8.44e-06	0.000143	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—RAF1—dilated cardiomyopathy	8.34e-06	0.000142	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	8.17e-06	0.000139	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	8.1e-06	0.000138	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	7.95e-06	0.000135	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	7.89e-06	0.000134	CbGpPWpGaD
Tamoxifen—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	7.79e-06	0.000132	CbGpPWpGaD
Tamoxifen—ABCB1—Metabolism—AGT—dilated cardiomyopathy	7.6e-06	0.000129	CbGpPWpGaD
Tamoxifen—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	7.16e-06	0.000122	CbGpPWpGaD
Tamoxifen—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	7.1e-06	0.000121	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	6.92e-06	0.000118	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	6.74e-06	0.000115	CbGpPWpGaD
Tamoxifen—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	6.07e-06	0.000103	CbGpPWpGaD
Tamoxifen—ESR1—Signaling Pathways—EGFR—dilated cardiomyopathy	5.72e-06	9.72e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	5.34e-06	9.08e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	5.2e-06	8.84e-05	CbGpPWpGaD
Tamoxifen—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	4.68e-06	7.96e-05	CbGpPWpGaD
